Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Medivir Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Medivir hat ein Gesamteigenkapital von SEK211.5M und eine Gesamtverschuldung von SEK0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen SEK266.4M bzw. SEK54.9M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

kr0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	kr153.50m
Eigenkapital	kr211.50m
Gesamtverbindlichkeiten	kr54.90m
Gesamtvermögen	kr266.40m

Jüngste Berichte zur Finanzlage

Recent updates

Is Medivir (STO:MVIR) In A Good Position To Invest In Growth?

Nov 09

Is Medivir (STO:MVIR) In A Good Position To Invest In Growth?

Jul 27

Is Medivir (STO:MVIR B) In A Good Position To Deliver On Growth Plans?

Jan 09

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: MVIRDie kurzfristigen Aktiva des Unternehmens (SEK158.5M) übersteigen seine kurzfristigen Passiva (SEK44.2M).

Langfristige Verbindlichkeiten: MVIRDie kurzfristigen Vermögenswerte des Unternehmens (SEK158.5M) übersteigen seine langfristigen Verbindlichkeiten (SEK10.7M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: MVIR ist schuldenfrei.

Schulden abbauen: MVIR hatte vor 5 Jahren keine Schulden.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: MVIR auf der Grundlage seines derzeitigen freien Cashflows über eine ausreichende Liquiditätsreserve für mehr als ein Jahr verfügt.

Vorhersage Cash Runway: MVIR verfügt über eine ausreichende Liquiditätsreserve für 1.6 Jahre, wenn der freie Cashflow weiterhin mit historischen Raten von 32.9 % pro Jahr wächst.

Medivir Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Is Medivir (STO:MVIR) In A Good Position To Invest In Growth?

Is Medivir (STO:MVIR) In A Good Position To Invest In Growth?

Medivir AB Announces Delisting of Paid Subscription Shares

Is Medivir (STO:MVIR B) In A Good Position To Deliver On Growth Plans?

Recent updates

Chief Executive Officer recently bought kr176k worth of stock

Medivir Aktiebolag (publ) Approves Board Appointments

Consensus revenue estimates increase by 21%

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates fall by 90%

Price target decreased by 8.2% to kr22.49

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Medivir AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

Medivir AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 20.000001 million.

New major risk - Shareholder dilution

Medivir AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 20.000001 million.

Medivir Presents the First Clinical Data with Fostrox + Lenvima At the Asco GI Scientific Congress

Medivir AB Announces Further Improved Clinical Benefit with Fostrox + Lenvima as Data from the Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancer

Price target decreased by 16% to kr23.39

Medivir AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 128.961315 million.

Medivir AB Announces Data from Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancers

Medivir AB Announces Updated Formulation of Fostrox Critical to Support Planned Study with Accelerated Approval Intent in Second Line HCC

Medivir AB Announces Updated Formulation of Fostrox Critical to Support Planned Study with Accelerated Approval Intent in Second Line HCC

Medivir AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 147.979713 million.

Is Medivir (STO:MVIR) In A Good Position To Invest In Growth?

Consensus revenue estimates fall by 78%

New major risk - Financial position

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Medivir AB (publ) to Report First Half, 2024 Results on Aug 22, 2024

Medivir AB (publ) to Report Q1, 2024 Results on Apr 30, 2024

New minor risk - Share price stability

Medivir AB (publ), Annual General Meeting, May 07, 2024

Medivir AB (Publ) Announces Resignation of Anette Lindqvist as Director

Medivir AB Announces All Patients in the Ongoing Phase 2A Study in Advanced Hepatocellular Car Car Car Carcinoma Has Now Dosed At Least Two Treatment Cycle

Medivir AB Reports Promising Interim Data, Including A First Complete Response in Phase 1B/2A Hcc Study with Fostrox in Combination with Lenvima

High number of new and inexperienced directors

Consensus revenue estimates increase by 47%, EPS downgraded

Independent Chairman of the Board recently bought kr374k worth of stock

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Medivir AB Announces 15th Patient with Advanced Liver Cancer Has Been Included in the Ongoing Phase 2A Study

Medivir AB Announces Formation of A Scientific Advisory Council

Is Medivir (STO:MVIR) In A Good Position To Invest In Growth?

Medivir AB Announces Patent Application for Fostrox Approval in China

Medivir AB Completes the Dose Escalation Part (Phase 1B) of the 1B/2A Study in Hcc and Focus on the Combination of Fostrox and Lenvima

Chief Executive Officer recently bought kr209k worth of stock

Price target increased by 14% to kr28.08

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 16%, revenue upgraded

Price target increased by 13% to kr27.96

Forecast to breakeven in 2024

Less than half of directors are independent

Medivir Completes A Successful Pre-IND Meeting with the FDA

Medivir AB (Publ) Appoints Pia Baumann as New Chief Medical Officer

Medivir AB (Publ) Appoints Nomination Committee

Medivir AB (publ) to Report Q2, 2023 Results on Aug 18, 2023

Medivir AB (publ) to Report Q1, 2023 Results on Apr 27, 2023

Medivir Aktiebolag (Publ) Announces Board Changes

Medivir AB (publ) to Report Fiscal Year 2021 Final Results on Apr 05, 2022

Medivir AB (Publ) Announces Phase II Study of Miv-711 for Osteoarthritis Shows Statistically Significant Reduction in Oa Pain

Medivir AB (publ) Announces Abstract for MIV-818 phase 1b monotherapy for ESMO Congress published

Medivir AB Announces Positive Data from the Remetinostat Phase II Study in Basal Cell Carcinoma Published in Clinical Cancer Research

Medivir Announces the Design of its Upcoming MIV-818 Combination Study

Medivir AB Announces Positive Results from Investigator-Initiated Phase II Clinical Study of Remetinostat in Patients with Squamous Cell Carcinoma

Medivir AB (publ), Annual General Meeting, May 05, 2021

Medivir AB Announces Delisting of Paid Subscription Shares

Medivir AB Enters into Licensing Agreement with Ubiquigent Limited for Preclinical Program USP7

New 90-day low: kr8.00

IGM Biosciences, Inc. Enters into Exclusive Licensing Agreement with Medivir for Birinapant

Is Medivir (STO:MVIR B) In A Good Position To Deliver On Growth Plans?

New 90-day low: kr8.25

Medivir AB (Publ) Renegotiates its agreement with TetraLogic Pharmaceuticals Corporation

New 90-day low: kr11.60

Earnings beat expectations, revenue disappoints

Third quarter 2020 earnings released: EPS kr0.19

New 90-day low: kr13.60

Medivir AB (publ) to Report Q1, 2021 Results on Apr 28, 2021